A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures by Bonafede, Machaon MK et al.
© 2010 Bonafede et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article 
which permits unrestricted noncommercial use, provided the original work is properly cited.
Patient Preference and Adherence 2010:4 147–156
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
147
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
10467
A retrospective database analysis of insulin use 
patterns in insulin-naïve patients with type 2 
diabetes initiating basal insulin or mixtures
Machaon MK Bonafede1
Anupama Kalsekar2
Manjiri Pawaskar2
Kimberly M Ruiz3
Amelito M Torres3
Karen R Kelly2
Suellen M Curkendall3
1Thomson Reuters Inc, Cambridge, 
Massachusetts, USA; 2Eli Lilly and 
Company, Indianapolis, Indiana, USA; 
3Thomson Reuters Inc, Washington, 
DC, USA
Correspondence: Machaon MK Bonafede 
Thomson Reuters Inc, 37 Lowell Street, 
Andover MA 01810, USA 
Tel +1-585-766-8622 
Fax +1-617-492-9365 
Email machaon.bonafede@
thomsonreuters.com
Objective: To describe insulin persistence among patients with type 2 diabetes initiating 
insulin therapy with basal insulin or insulin mixtures and determine factors associated with 
nonpersistence.
Research design and methods: The Thomson Reuters MarketScan® databases were used to 
retrospectively analyze insulin-naïve patients with type 2 diabetes by initiating insulin therapy. 
Insulin use was described using a variety of measures. The persistence to insulin was described 
using both a gap-based measure and the number of claims measure.
Results: Patients in the basal insulin cohort (N = 15,255) primarily used insulin analogs (88.1%) 
and vial and syringe (97%). Patients in the mixture cohort (N = 2,732) were more likely to initiate 
on human insulin mixtures (62.5%) and vial and syringe (68.1%). Average time between insulin 
refills was 80 and 71 days for basal and mixture initiators, respectively. Nearly, 75% of basal 
insulin initiators and 65% of insulin mixture initiators had a 90-day gap in insulin prescriptions. 
More than half of all the patients had at least one insulin prescription per quarter. Patients 
initiating with insulin analogs were more likely to be persistent compared with those initiating 
with human insulin across both cohorts and measures of persistence (P , 0.001).
Conclusion: Persistence to insulin therapy is poorer than one would anticipate, but appears to 
be higher in users of insulin analogs and insulin mixtures.
Keywords: insulin persistence, basal insulin, insulin mixtures
Introduction
Type 2 diabetes is a common and expensive disease, with 17.5 million diagnosed cases 
and $174 billion in acute-care costs in the United States in 2007.1 The goal of type 2 
diabetes treatment is to maintain a glycosylated hemoglobin (HbA1c) of ,7%.2 To 
meet this goal, many patients with type 2 diabetes eventually require insulin therapy 
to maintain glycemic control because of progressive β-cell dysfunction. Health care 
providers and patients are often reluctant to initiate insulin therapy, as this therapy is 
intended to be a permanent change and requires strict adherence and persistence to diet 
and medication compared with oral antihyperglycemic agents. A significant percent 
of patients with diabetes experiences difficulty in taking insulin as prescribed by their 
doctor. For example, in a review article, Cramer3 reported that persistence to insulin 
varies but is often quite low and three reviewed studies reported that 16%–49% of 
patients are persistent at 6–12 months.4–6 Research also suggests that factors related 
to injection,7 complexity of the medication regimen,3 and higher frequency dosing 
schedules8,9 are key barriers to insulin therapy. Thus, several treatment-related factors 
may be significant barriers to successful long-term treatment for some patients.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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The primary objective of this study was to describe the 
persistence to insulin among insulin-naïve patients with 
type 2 diabetes, who initiated insulin therapy with basal 
(long-acting) insulin or mixtures. The secondary objective 
was to determine risk factors for poor persistence with 
insulin therapy.
Research design and methods
This study used a retrospective approach using administrative 
claims data. Two MarketScan® research databases from 
Thomson Reuters were used in this study: the Commercial 
Claims and Encounters (Commercial) and the Medicare 
Supplemental and Coordination of Benefits (Medicare 
Supplemental and COB) databases. The Commercial database 
contains the details of inpatient, outpatient, emergency room 
(ER), and outpatient prescription drug experience of several 
million individuals and their dependents (annually), who 
were covered under a variety of fee-for-service and capitated 
health plans, including exclusive provider organizations, 
preferred provider organizations, point of service plans, 
indemnity plans, and health maintenance organizations. 
The overall database includes individuals from over 100 
self-insured large employers and health plans. The Medicare 
Supplemental and COB database contains the healthcare 
experience of individuals with Medicare Supplemental 
insurance paid for by employers. Because it covers an 
older population than does the Commercial database, the 
Medicare Supplemental database is a key data source. Both 
the Medicare-covered portion of payment (represented as 
COB amount or COB) and the employer-paid portion are 
included in this database.
Inclusion criteria
Patients had to be new insulin initiators (basal or mixtures) 
between July 1, 2001, and December 31, 2006 (index date). 
Table 1 provides a list of insulins included in this study, which 
are classified by types: human vs analog and basal vs mixture. 
A 6-month preperiod was used to establish new insulin use, a 
diagnosis of type 2 diabetes (identified by ICD-9-CM codes), 
and the presence of stable diabetic therapy, as evidenced by 
having at least two prescriptions for exenatide (Byetta®) or 
an oral antidiabetic agent; the two oral antidiabetic agents 
could be for the same or different agents; patients were not 
required to use exenatide or oral antidiabetic agents in the 
postindex period. Subjects had to be enrolled in a qualified 
health plan with concurrent continuous pharmacy enrollment 
Table 1 Insulin types and examples
Class Generic name Brand name Type
Basal Insulin human isophane  
(NPH)
Humulin N;  
Novolin N;  
Relion/Novolin N;  
Insulatard
Human
Basal Insulin human zinc  
(Lente)
Humulin L;  
Novolin L
Human
Basal Insulin human zinc,  
extended (Ultralente)
Humulin U Human
Basal Insulin detemir Levemir Analog
Basal Insulin glargine,  
Recombinant
Lantus Analog
Insulin mixtures Insulin human isophane  
(NPH)/Insulin human regular
Humulin 50/50;  
Humulin 70/30
Human
Insulin mixtures Insulin human isophane  
(NPH)/Insulin human regular
Novolin 70/30;  
Relion/Novolin 70/30
Human
Insulin mixtures Insulin lispro/ 
Insulin lispro protamine
Humalog mix 50/50;  
Humalog mix 75/25
Analog
Insulin mixtures Insulin aspart/ 
Insulin aspart protamine
Novolog mix 70/30 Analog
Mealtime Insulin aspart, recombinant Novolog Analog
Mealtime Insulin glulisine Apidra Analog
Mealtime Insulin lispro, recombinant Humalog; lispro-PFC Analog
Mealtime Insulin human regular Humulin R;  
Novolin R;  
Relion/Novolin R
Human
Mealtime Insulin human regular,  
buffered
Humulin BR;  
Velosulin BR
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for a 21-month period spanning the 6-month preindex period 
through the 15-month study period between January 1, 2001, 
and March 31, 2008. A moving target index data approach 
was used to maximize sample size and minimize the impact 
of seasonal effects (such as annual caps) on utilization.
Exclusion criteria
Patients were excluded if they had evidence of gestational 
diabetes (ICD-9-CM code of 648.8x), had evidence of type 1 
diabetes (ICD-9-CM code of 250.x1 or 250.x3 or DRG 295), 
or used inhaled insulin or an insulin pump anytime in the 
observation period. In order to create a more homogenous 
patient population of insulin initiators, patients were also 
excluded if they used mealtime (short-acting) insulin or both 
basal and mixed insulins in the postindex period. Patients 
with only one insulin prescription claim were also excluded 
from this analysis.
Insulin use and variables of interest
Index insulin characteristics such as insulin type (human vs 
analog) and administration (pen vs vial and syringe) were 
noted.
Several study variables were used to describe insulin use. 
These include the following:
1.  Number of prescription claims for index insulin at 3, 6, 
and 12 months
2.  Average daily insulin supply calculated at 3, 6, and 
12 months postindex date by calculating the total insulin 
supply in mL dispensed and dividing by the number of 
days in that period
3.  Average time between refills of index insulin
4.  Proportion that switched to a different insulin type or a 
different insulin administration.
Insulin persistence measures
Daily adherence to insulin, defined as, “the extent to which 
a patient acts in accordance with the prescribed interval and 
dose of a dosing regimen,” was of interest but could not be 
determined from a database of prescription claims.10 This 
study instead focused on evaluating persistence at 12 months, 
defined as the time from therapy initiation to discontinuation, 
including a limit on the days between fills.10   Persistence was 
evaluated at 12 months by the absence of gaps between refills 
(measure 1) or the number of refills within a prespecified 
period (measure 2). Under measure 1, patients were consid-
ered persistent at 3 months if they did not have a 90-day gap 
in index insulin prescriptions, which started prior to the end of 
the third month. Persistence at 6 and 12 months were defined 
similarly but relative to the end of the sixth and twelfth months, 
respectively. Under measure 2, patients were considered per-
sistent at 3 months if they had two index insulin prescriptions 
in the first 4 months. Patients were considered persistent at 6 
months if they had at least three claims in the first 7 months, 
including at least one in 1–3 months and at least one claim in 
4–6 months. Patients were considered persistent at 12 months 
if they had at least four insulin prescriptions in 12 months fol-
lowing their index prescription, with at least one index insulin 
prescription in each quarter. Measure 1   represents a standard 
definition of persistence,10 and   measure 2 is a more lenient 
measure and hence was included as a sensitivity analysis. 
Nonpersistence, as determined by these measures, does not 
imply a permanent discontinuation from insulin and may be 
a marker for intermittent use.
Persistent and nonpersistent patients were compared using 
standard tests of statistical significance. Chi-square tests were 
used to evaluate the statistical significance of differences for 
categorical variables; however, two-tailed t-tests and analysis of 
variance were used for continuous variables. A series of logistic 
regression models were used to examine factors associated 
with being persistent with insulin therapy at 12 months. Fac-
tors included age, gender, location, type of   insurance, insulin 
type, insulin administration mode, Deyo Charlson Comorbidity 
Index (described by Deyo et al11), presence of hospitalization, 
presence of ER visit, presence of diabetes complications, 
presence of macrovascular complications, presence of mental 
health disorders, count of other diabetes medications, and 
average copayment per prescription of insulin. An alpha of 
0.05 was used for all analyses. Due to the larger sample size, 
a power calculation was not performed.
Results
Of the 505,898 patients with a index prescription of basal or 
mixture insulins, 69,318 met the inclusion criteria, of which 
17,987 patients also met the exclusion criteria and formed 
the final sample for this analysis. Nearly, 85% of these 
patients (N = 15,255) initiated insulin therapy with basal 
insulin using insulin analogs (88.1%) and vial and syringe 
(97%) (Table 2). Less than 1% of the basal insulin i  nitiators 
switched to a different insulin type (analog or human) or 
different insulin administration mode in the 12 months 
  following index insulin prescription. Conversely, in the 
insulin mixture cohort (N = 2,732), most patients initiated 
insulin using human insulin mixtures (62.5%) and vial and 
syringe (68.1%). Approximately, 7% of patients switched to 
a different insulin type and insulin administration mode in 
the 12 months following index insulin prescription.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Basal insulin initators used an average of two other 
antidiabetic medications in the follow-up period compared 
with an average of 1.4 for insulin mixture initiators. Both 
basal and insulin mixture initiators had similar prevalence of 
diabetes complications (22% and 24%, respectively), macro-
vascular complications (49% and 51%, respectively), and 
mental health disorders (5% and 6.5%, respectively). Mean 
Deyo Charlson Comorbidity Index scores were also similar 
(1.9 for basal insulin initiators and 2.1 for insulin mixture 
initiators).
As shown in Table 2, the mean number of claims for basal 
and mixture insulins increased over time, but the average 
daily supply decreased. For eg, basal insulin index patients 
filled an average of 2.07 prescriptions in the first 3 months, 
3.4 prescriptions in the first 6 months, and 5.99 in the whole 
year of the study, which corresponds to 0.69 prescription fills 
per month in the first 3 months and 0.57 and 0.50 prescription 
fills per month in the subsequent time periods. The average 
daily supply follows a similar, albeit less pronounced trend 
over the same time periods, dropping from 0.25 mL (25 IU) 
per day to 0.20 mL (20 IU) per day and eventually to 0.18 mL 
(18 IU) per day. The average time between refills over 
12 months was slightly higher among basal index patients 
(mean: 80.1 days, median: 67.4 days) than mixture index 
patients (mean: 71.3 days, median: 55.5 days).
Using measure 1, persistence in the basal cohort was 
50.6%, 38.5%, and 26.5%; and persistence in the mixture 
cohort was 58.5%, 47.6%, and 35.0% at 3, 6, and 12 months, 
respectively. In other words, almost three-quarters (73.5%) 
of the patients who initiated insulin therapy with basal 
  insulin had a 90-day gap between prescriptions at some 
point during the study period. Similarly, more than half of 
the mixture index patients (65.0%) had a 90-day gap between 
prescriptions. The start of a 90-day gap was, on average, 
80 days and 90.6 days for basal insulin and insulin mixture 
initiators, respectively, after their index insulin prescription. 
Among basal insulin initiators, 38.4% had a 90-day gap 
immediately after their index prescription, and 6.7% had a 
90-day gap that start within 30 days of their index prescrip-
tion. Among insulin mixture initiators, 32.2% had a 90-day 
gap immediately after their index prescription, and 7.2% 
had a 90-day gap that start within 30 days of their index 
prescription. The majority of patients with a 90-day gap had 
another prescription following the period; 86.9% of basal 
index patients and 81.5% of mixture index patients restarted 
insulin following a 90-day gap. The time between the start of 
the 90-day gap and the next prescription was similar in both 
groups (basal index mean: 143.4 days, median: 120 days; 
mixture index mean: 145.9 days, median: 121 days).
Because measure 2 allowed for longer time between 
refills, more patients were likely to be classified as persis-
tent with this measure. Using measure 2, persistence was 
83.4%, 67.1%, and 55.8% among basal insulin initiators and 
86.7%, 71.0%, and 59.1% among insulin mixture initiators 
at 3, 6, and 12 months, respectively. The agreement between 
  measures 1 and 2 at 3, 6, and 12 months was 67%, 71%, and 
71% among basal insulin initiators and 72%, 77%, and 76% 
among insulin mixture initiators, respectively. Agreement 
was measured as the number of concordant pairs divided by 
the number of discordant pairs.
Table 3 describes basal and mixture insulin initiators 
according to their persistence status determined by measure 2. 
Table 2 Insulin use
Basal insulin (N = 15,255) Insulin mixtures (N = 2,732)
Mean Median IQ range Mean Median IQ range
No. of claims
3 mo 2.07 2 (1, 3) 2.42 2 (1, 3)
6 mo 3.40 3 (2, 4) 3.97 4 (2, 5)
12 mo 5.99 5 (4, 8) 6.93 6 (4, 9)
Quantity per day (mL)
3 mo 0.25 0.22 (0.17, 0.33) 0.31 0.33 (0.22, 0.33)
6 mo 0.20 0.17 (0.11, 0.25) 0.26 0.22 (0.17, 0.33)
12 mo 0.18 0.16 (0.11, 0.22) 0.22 0.19 (0.12, 0.30)
Time between refills (days)
12 mo 80.11 67.40 (45.20, 95.67) 71.32 55.50 (27.92, 84.00)
Time until change in insulin administration (days): pen vs vial and syringe
12 mo 192.80 189 (97, 286) 126.71 92.5 (22.5, 224.5)
Time until change in insulin type (days): human vs analog
12 mo 164.03 159 (66, 257) 139.87 118 (49, 225)Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 3 Demographic and clinical characteristics
Basal insulin initiators Insulin mixture initiators
Persistent  
N = 8,515
Nonpersistent 
N = 6,740
P value Total  
N = 15,255
Persistent 
N = 1,615
Nonpersistent  
N = 1,117
P value Total  
N = 2,732
Mean % 
(SD)
Mean % 
(SD)
Mean % 
(SD)
Mean % 
(SD)
Mean % 
(SD)
Mean % 
(SD)
Gender: Female 43.43% 45.43% 44.31% 47.93% 50.13% 48.83%
Age (mean, SD) 59.44  
(11.38)
60.01  
(12.17)
0.003 59.69  
(11.74)
60.67  
(11.89)
59.87  
(12.49)
0.093 60.34  
(12.14)
Age group
  ,18 0.07% 0.06% ,0.0001 0.07% 0.06% 0.00% 0.321 0.04%
  18–34 1.12% 1.65% 1.35% 1.49% 1.97% 1.68%
  35–44 7.00% 7.45% 7.20% 6.69% 7.97% 7.21%
  45–54 25.01% 23.84% 24.50% 21.98% 24.26% 22.91%
  55–64 37.49% 33.87% 35.89% 33.37% 31.87% 32.76%
  65–74 18.27% 19.15% 18.66% 22.66% 20.14% 21.63%
  $75 11.04% 13.98% 12.34% 13.75% 13.79% 13.76%
Location
  Urban 77.79% 79.58% 0.026 78.58% 78.20% 77.08% 0.153 77.75%
  Rural 21.90% 20.10% 21.11% 21.61% 22.29% 21.89%
  Unknown 0.31% 0.31% 0.31% 0.19% 0.63% 0.37%
Index insulin type
  Human 10.43% 13.71% ,0.0001 11.88% 59.20% 67.23% ,0.0001 62.48%
  Analog 89.57% 86.29% 88.12% 40.80% 32.77% 37.52%
Index insulin administration
  Vials and syringes 97.32% 96.51% 0.004 96.96% 67.99% 68.31% 0.860 68.12%
  Pens 2.68% 3.49% 3.04% 32.01% 31.69% 31.88%
Change in index insulin
    Human vs analog 
change
2.50% 2.52% 0.935 0.25% 7.12% 6.09% 0.288 6.70%
    Mean time to  
change
159.25  
(105.94)
170.02  
(112.85)
0.338 164.03  
(109.05)
145.43  
(104.95)
130.47  
(106.70)
0.356 139.87  
(105.56)
    Pen vs vial and  
syringe change
0.73% 0.76% 0.838 0.74% 8.48% 6.00% 0.015 7.47%
    Mean time to  
change
185.82  
(106.88)
201.27  
(106.99)
0.446 192.80  
(106.73)
135.69  
(115.19)
108.34  
(103.73)
0.102 126.71  
(112.04)
Insulin use: 12 months
    No. of index  
insulin claims
7.83  
(3.08)
3.69  
(1.52)
,0.0001 6.00  
(3.25)
9.13  
(3.63)
3.74  
(1.88)
,0.0001 6.93  
(4.03)
    Index insulin  
quantity per day
0.23  
(0.092)
0.11  
(0.05)
,0.0001 0.18  
(0.10)
0.30  
(0.13)
0.12  
(0.07)
,0.0001 0.22  
(0.14)
    Time between  
index insulin claims
57.95  
(22.99)
108.11  
(67.41)
,0.0001 80.11  
(54.07)
49.32  
(20.65)
103.12  
(72.36)
,0.0001 71.32  
(55.60)
Concomitant medications
    Diabetes  
medication count
2.00  
(0.96)
2.12  
(1.00)
,0.0001 2.05  
(0.98)
1.27  
(1.05)
1.66  
(1.05)
,0.0001 1.43  
(1.06)
    Cardiovascular 
medication count
3.81  
(2.21)
3.79  
(2.32)
0.496 3.80  
(2.26)
3.95  
(2.38)
3.79  
(2.42)
0.076 3.88  
(2.40)
Copayment burden
    Total cost of 
prescriptions
$5,278  
($3,808)
$4,612  
($3,444)
,0.0001 $4,984  
($3,666)
$5,075  
($4,580)
$4,362  
($5,258)
,0.001 $4,783  
($4,881)
    Copay per  
insulin prescription
$18.63  
($15.42)
$20.10  
($18.14)
,0.0001 $19.28  
($16.69)
$17.28  
($14.28)
$18.72  
($16.85)
0.017 $17.87  
($15.40)
Comorbidities
    Deyo Charlson 
Comorbidity index
1.86 (1.46) 1.96 (1.60) ,0.001 1.90  
(1.52)
2.10  
(1.72)
2.06  
(1.74)
0.477 2.08  
(1.73)
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Table 3 (Continued)
Basal insulin initiators Insulin mixture initiators
Persistent  
N = 8,515
Nonpersistent 
N = 6,740
P value Total  
N = 15,255
Persistent 
N = 1,615
Nonpersistent  
N = 1,117
P value Total  
N = 2,732
Mean % 
(SD)
Mean % 
(SD)
Mean % 
(SD)
Mean % 
(SD)
Mean % 
(SD)
Mean % 
(SD)
    Diabetes  
complications
20.88% 23.09% 0.001 21.86% 24.21% 23.19% 0.537 23.79%
    Macrovascular 
complications
48.40% 50.50% 0.010 49.33% 51.52% 50.94% 0.767 51.28%
  Any mental health 4.67% 5.95% ,0.0001 5.24% 6.81% 6.00% 0.396 6.48%
Diabetes-related events
    Inpatient  
admissions
0.41% 0.89% 0.002 0.62% 0.99% 0.54% 0.416 0.81%
    Mean length  
of stay
4.96 (3.63) 6.79 (6.81) 0.143 6.12 (5.89) 5.50 (6.27) 5.25 (3.79) 0.929 5.43 (5.62)
  ER use 0.34% 0.42% 0.566 0.37% 0.43% 0.45% 0.956 0.44%
Cardiovascular-related events
    Inpatient  
admissions
3.35% 4.05% 0.233 3.66% 4.52% 4.92% 0.786 4.69%
    Mean length  
of stay
3.28 (3.12) 3.83 (3.45) 0.050 3.55 (3.29) 3.44 (3.71) 4.74 (4.64) 0.082 4.00 (4.17)
  ER use 1.54% 1.99% 0.035 1.74% 2.41% 2.15% 0.649 2.23%
Abbreviations: SD, standard deviation; ER, emergency room.
Across basal insulin and mixture insulin initiators, age, gender, 
use of human insulin, polypharmacy, and copayment burden 
were significantly associated with persistence status.
The average number of claims and the average quantity of 
insulin per day were higher for patients who were persistent. 
Among basal insulin initiators, patients who were persistent 
had an average of 9.7 claims compared with an average of 
4.7 claims for nonpersistent patients (measure 1). Similarly, 
persistent patients averaged 0.28 mL (28 IU) of insulin per 
day compared with 0.14 mL of insulin per day for non-
persistent patients (data not shown in table). The same trends 
observed for measure 2, persistent patients had an average 
of 7.8 claims and 0.23 mL (23 IU) per day compared with 
an average of 3.7 claims and 0.11 mL (11 IU) per day for 
nonpersistent patients. Among insulin mixture initiators, the 
differences were more pronounced: patients without a 90-day 
gap had an average of 10.7 claims and 0.35 mL (35 IU) per 
day in the follow-up period compared with an average of 
4.9 claims and 0.16 mL (16 IU) per day among patients with 
a 90-day gap during the follow-up period. The difference was 
also present for measure 2; persistent patients had an average 
of 9.1 claims and 0.30 mL (30 IU) per day compared with 
3.7 claims and 0.12 mL (12 IU) per day for nonpersistent 
patients. The average quantity of insulin per prescription was 
similar for persistent and nonpersistent patients (basal insulin 
initiators: 10.8 mL vs 10.9 mL; insulin mixture initiators: 
11.9 mL vs 11.8 mL).
The majority of insulin initiators had a 90-day 
prescription gap; 73.5% of basal insulin initiators and 64.0% 
of insulin mixture initiators had a 90-day gap in their first 
year of insulin use. Among these patients with a 90-day 
gap, the average time from index to the start of the 90-day 
gap was 80 days (SD = 49 days) for basal insulin initiators 
and 91 days (SD = 60 days) for insulin mixture initiators. 
The majority of insulin initiators with a 90-day gap had 
an insulin prescription following the gap (86.7% of basal 
initiators, 81.5% of insulin mixture initiators). Among these 
patients with a prescription following a 90-day gap, the 
average time between the start of the prescription gap and 
next prescription was 143 days (SD = 120 days) for basal 
insulin initiators and 146 days (SD = 121 days) for insulin 
mixture initiators.
Multivariate results: persistence at  
12 months (Table 4)
Basal insulin initiators
By both persistence measures, women were slightly less 
likely to be persistent than men, with odds ratios (OR) of 0.94 
(95% confidence interval [CI]: 0.87–1.01, P = 0.074) and 
0.93 (95% CI: 0.87–0.99, P = 0.022), respectively. Patients 
younger than 35 years and those older than 65 years were 
less likely to be persistent at 12 months by both insulin per-
sistence measures compared with patients aged 45–54 years. 
Rural location was positively associated with persistence Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Table 4 Multivariate models predicting persistence
Odds ratio (95 CI)
Sample size Basal cohort (N = 15,255) Mixture cohort (N = 2,732)
Variable Persistence at 12 months  
measure 1
Persistence at 12 months  
measure 2
Persistence at 12 months 
measure 1
Persistence at 12 
months measure 2
Female 0.94 (0.87, 1.01) 0.93 (0.87, 0.99)a 1.00 (0.85, 1.17) 0.93 (0.80, 1.09)
Age
  ,35 0.63 (0.45, 0.88)a 0.66 (0.50, 0.87)b 0.76 (0.39, 1.46) 0.88 (0.48, 1.60)
  35–44 0.98 (0.85, 1.14) 0.90 (0.78, 1.03) 0.96 (0.68, 1.35) 0.94 (0.68, 1.31)
  55–64 0.92 (0.84, 1.01) 1.05 (0.96, 1.14) 0.97 (0.78, 1.21) 1.13 (0.91, 1.39)
  65–74 0.69 (0.62, 0.78)c 0.91 (0.82, 1.01) 0.97 (0.76, 1.24) 1.21 (0.95, 1.54)
  .74 0.69 (0.60, 0.79)c 0.77 (0.69, 0.87)c 0.80 (0.60, 1.07) 1.07 (0.82, 1.41)
Region
  North Central 0.98 (0.85, 1.14) 0.99 (0.87, 1.13) 0.85 (0.61, 1.20) 1.27 (0.91, 1.77)
  South 1.07 (0.92, 1.24) 0.92 (0.81, 1.04) 0.84 (0.60, 1.17) 1.18 (0.85, 1.63)
  West 1.17 (1.00, 1.38) 0.95 (0.82, 1.09) 0.88 (0.61, 1.27) 1.17 (0.82, 1.68)
  Unknown 0.75 (0.36, 1.58) 0.99 (0.56, 1.77) 0.16 (0.02, 1.24) 0.60 (0.18, 1.99)
Rural 1.29 (1.18, 1.41)c 1.11 (1.03, 1.21)a 1.12 (0.91, 1.36) 0.98 (0.81, 1.19)
Capitated insurance 1.26 (1.14, 1.39)c 1.16 (1.06, 1.27)b 1.27 (1.01, 1.59)a 1.13 (0.91, 1.41)
Index
  human 0.73 (0.65, 0.83)c 0.70 (0.63, 0.77)c 0.68 (0.58, 0.81)c 0.69 (0.58, 0.81)c
  pen 0.64 0.50, 0.82)c 0.78 (0.65, 0.94)b 0.94 (0.79, 1.13) 0.99 (0.83, 1.17)
Deyo Charlson  
Comorbidity Index
0.99 (0.96, 1.02) 0.98 (0.96, 1.01) 0.98 (0.93, 1.04) 1.00 (0.95, 1.06)
ER admissions 0.86 (0.65, 1.15) 0.90 (0.71, 1.13) 0.79 (0.46, 1.34) 1.08 (0.66, 1.77)
Inpatient admissions 0.86 (0.69, 1.07) 0.79 (0.66, 0.95)a 0.79 (0.52, 1.19) 0.95 (0.64, 1.40)
Diabetes Complications 1.00 (0.90, 1.10) 0.94 (0.86, 1.02) 1.00 (0.81, 1.25) 1.03 (0.83, 1.27)
Count of OAD agents 1.02 (1.00, 1.04)a 1.02 (1.01, 1.04)b 1.02 (0.98, 1.06) 1.02 (0.98, 1.06)
Macrovascular complications 0.94 (0.87, 1.02) 0.93 (0.87, 1.00)a 1.02 (0.86, 1.22) 0.96 (0.81, 1.14)
Mental health disorders 0.81 (0.68, 0.96) a 0.79 (0.68, 0.91)b 0.99 (0.71, 1.37) 1.14 (0.83, 1.57)
Average copay for insulin 0.99 (0.99, 0.99)c 0.99 (0.99, 1.00)c 0.99 (0.99, 1.00)a 0.99 (0.99, 1.00)a
Note: Reference groups: age 45–54; Region: North East; Noncapitated Insurance; aDenotes P , 0.05; bDenotes P , 0.01; cDenotes P , 0.001.
Abbreviations: ER, emergency room; OAD, oral antidiabetic.
at 12 months, with an OR of 1.29 (95% CI: 1.18–1.41, 
P , 0.001) for measure 1 and 1.11 (95% CI: 1.03–1.21, 
P = 0.01) for measure 2.
The use of human insulin was significantly associ-
ated with poorer persistence (measure 1: OR = 0.73; 
95% CI: 0.65–0.83, P , 0.0001; measure 2: OR = 0.70; 
95% CI: 0.63–0.77, P , 0.0001). Use of insulin pen 
at index was also associated with poorer persistence 
by both measures (measure 1: OR = 0.64; 95% CI: 
0.50–0.82, P , 0.0001; measure 2: OR = 0.78; 95% 
CI: 0.65–0.94, P = 0.009)
Of the clinical variables, the presence of a mental 
health disorder, which included a diagnosis of depression, 
was consistently associated with decreased persistence 
at 12 months by both measures (measure 1: OR = 0.81; 
95% CI: 0.68–0.96, P = 0.017; measure 2: OR = 0.79; 
95% CI: 0.68–0.91, P = 0.002).Increasing the count of 
oral antidiabetic agent classes was associated with a 
statistically significant increase in persistence by both 
measures; however, this increase was modest with an OR 
of 1.02 for both measures (measure 1: 95% CI: 1.00–1.04, 
P = 0.016; measure 2: 95% CI: 1.01–1.04, P = 0.004). 
Similarly, increasing the average copayment for insulin 
by $1 decreased the odds of being persistent at 12 months 
by 1% for both persistence measures (P , 0.001 for both 
measures). Regional location, comorbid burden measured 
by the Deyo Charlson Comorbidity Index, presence of ER 
or hospital admissions, and presence of diabetes or macro-
vascular complications were not statistically significantly 
associated with persistence.
Insulin mixture initiators
Among mixed insulin index patients, none of the 
demographic or clinical characteristics were statistically 
significantly associated with insulin persistence at 12 
months.
The use of human insulin was associated with decreased 
persistence at 12 months by both measure 1 (OR = 0.68; Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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95% CI: 0.58–0.81, P , 0.0001) and measure 2 (OR = 0.69; 
95% CI: 0.58–0.81, P , 0.0001). The use of a pen device 
was not statistically significantly associated with persistence 
at 12 months by both measures (P . 0.5).
Similar to the basal index insulin patients, the average 
copayment for insulin was negatively associated with insulin 
persistence at 12 months, such that a $1 increase in aver-
age copayment was associated with a 1% decrease in the 
odds of persistence at 12 months (P = 0.012 and P = 0.022, 
respectively).
Conclusions
Insulin use was much lower than expected in the first year 
following insulin initiation among insulin-naïve patients with 
type 2 diabetes. Furthermore, the proportion of patients who 
were persistent with insulin decreased over time,   dropping 
from 83.4% at 3 months to 67.1% at 6 months and to 55.8% 
at 12 months among basal insulin initiators and dropping 
from 86.7% at 3 months to 71.0% at 6 months and to 59.1% 
at 12 months among insulin mixture initiators, as deter-
mined by the more lenient of the two measures utilized in 
this study (ie, measure 2). Using a more conservative gap-
based persistence measure (ie, measure 1), 50.6%, 38.5%, 
and 26.5% of basal insulin initiators were persistent at 3, 6, 
and 12 months, respectively; 58.5%, 47.6%, and 35.0% of 
insulin mixture initiators were persistent over the same time 
periods. Although it is not a measure of discontinuation, the 
presence of a 90-day gap is an indication of poorer persistence 
with insulin, particularly, if that gap starts immediately after 
insulin initiation. Although the majority of patients had a 
90-day gap sometime during their first year of insulin use, 
over one-third of all insulin initiators had a 90-day gap fol-
lowing their first insulin claim.
It is important to distinguish between persistence and 
permanent medication discontinuation. In this study, persis-
tence was defined as a relatively short-term gap (90 days by 
persistence measure 1) in insulin prescription coverage over 
a relatively short time period (3, 6, or 12 months).   According 
to Sikka et al,12 once patients exceed the permissible gap 
in prescriptions (90 days in this study), they are no longer 
considered persistent, even if they have prescription fills 
following the permissible gap. Over 80% of patients with 
an insulin prescription gap of 90 days or greater had addi-
tional insulin prescription fills after the gap. Although these 
patients were nonpersistent by the study definitions, they did 
not completely discontinue insulin therapy and need further 
investigation. Persistence measure 2 was developed, in part, 
as a sensitivity analysis around the gap-based definition 
of measure 1, allowing for substantially longer intervals 
between prescriptions to be considered persistent. Even by 
this lenient measure, only 55%–60% of insulin initiators were 
persistent at the end of first year.
There is no validated measure available to measure 
insulin adherence and persistence. The gap period is com-
monly used as a measure for persistence to oral antidiabetic 
medications and is well accepted in the literature. Similarly, 
an early formulation of persistence measure 2 incorporated 
the current number of claims structure and a requirement 
of 0.10 mL index insulin per day, on average. Descriptive 
analysis of the average daily supply of insulin did not provide 
a clear, clinically relevant cut off that did not appear arbitrary. 
Descriptive analysis also indicated that the number of claims 
requirement largely drove persistence determination. Both 
of these reasons support excluding insulin quantity per day 
from persistence determination.
It is possible that patients with prescription gaps of at 
least 90 days (nonpersistent by measure 1) were stockpiling 
insulin, potentially causing them to be misclassified as non-
persistent. This did not appear to be the case as patients with 
prescription gaps of 90 days had significantly lower average 
insulin supplies per day (0.14 mL vs 0.28 mL among basal 
insulin initiators).
In spite of these limitations, our results were consistent 
with other recent research. For example, Cooke et al13 found 
that 28.7% of new basal insulin initiators was persistent at 
12 months. They also defined persistence as the time (in 
months) between the first and last insulin fill plus the days 
supply of the last insulin prescription. This current study was 
more conservative in that a 90-day gap constituted nonper-
sistence with insulin. Cooke et al also excluded patients who 
used any mealtime insulin in the postindex period, matching 
the exclusion criteria of this current study. Hertz et al14 also 
conducted a retrospective database analysis and reported 
that only 37.0% of new insulin initiators was persistent with 
insulin therapy at 12 months following index   treatment. 
Similarly, in an evaluation of glargine vs exenatide, Fabunmi 
et al15 used a 90-day gap to evaluate persistence and deter-
mined that less than 60% of insulin glargine initiators were 
persistent at 12 months.
Nearly 2,779 insulin users were excluded from this 
analysis because they only had one prescription of their 
index insulin. These patients may have required insulin 
for acute, high hyperglycemia events (ie, they only needed 
one prescription for insulin, however unlikely that may be). 
These patients may have also discontinued insulin altogether 
after one prescription. Future research should examine this Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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subgroup of patients to better understand their reasons for 
discontinuation.
There is evidence that dislike of injections is related to 
the discontinuing of insulin use, suggesting that the use of 
insulin pens would be associated with better persistence or 
adherence than insulin vial and syringe.4 Other recent   studies 
have found that insulin pens and vial and syringe have similar 
adherence profiles.16 This current study appears to support the 
latter standpoint; however, comparing vials and syringe vs 
insulin pens was not an explicit study objective. Furthermore, 
the availability of the products may have driven comparisons 
of insulin type or delivery system. Among basal insulin index 
patients, the findings regarding delivery system (pen vs vial 
and syringe) are likely due largely to the unequal   distribution 
of products available; thus, for mixture insulin index patients, 
index insulin administration was not a significant predictor 
of persistence.
Multivariate analysis also indicated that human   insulin 
was consistently associated with poorer persistence 
than   analog insulin. This may be due to lower risk of 
  hypoglycemia and greater flexibility in dosing associated 
with analog insulin. However, provider-related   prescribing 
preferences for analog or human insulin may have also 
  contributed to this finding.
The finding that higher counts of concomitant   medications 
were positively associated with insulin persistence is 
  inconsistent with existing literature.7 This association could 
be due, in part, to the fact that the prescription of additional 
classes of oral antidiabetic agents is a result of healthcare 
utilization and monitoring. On the other hand, the presence of 
comorbid conditions, such as macrovascular complications, 
was associated with poorer persistence.
While interpreting these results, it is also important to 
remember limitations of claim databases. Claim data studies 
are subject to incomplete recording of data or miscoding, 
particularly with variables that do not drive service payments. 
These recording errors are most likely to be random errors; 
therefore, the impact on study results is likely minimal, 
if any. Further, the data source only includes adjudicated 
claims, minimizing the risk of data errors and omissions. 
Similarly, free insulin samples, which are not captured in 
this dataset, may have caused this study to underestimate 
insulin use; however, there is no reliable way to estimate 
the magnitude of this limitation.
Little is known about physician behavior, such as   potential 
channeling of patients to a particular therapy based on infor-
mation not captured in the claims history. The absence of 
lab or medical record data further limits the ability of this 
current study to understand physicians’ decision making and 
  prescribing practices. It also limits the ability to evaluate 
other lifestyle approaches to managing diabetes relative to 
insulin use and persistence. Furthermore, physician instruc-
tions to patients or individual dosing guidelines are unknown. 
This study only captures prescribed doses that a doctor writes 
and a patient fills. Finally, because glycemic control was 
not available in the dataset, we are limited in our ability to 
interpret results in relation to therapeutic needs of patients, 
eg, some patients may have discontinued insulin due to high 
risk of hypoglycemia. It is also possible that a patient may 
have been prescribed insulin in response to an acute glycemic 
event, making the patient appear nonpersistent with insulin 
following the acute insulin episode. Similarly, this current 
study does not capture how long a patient has had diabetes 
or the length of diabetes treatment, both of which may play 
a role in clinical decision making regarding the use of insulin 
and potentially impact persistence measures 1 and 2.
In conclusion, in a cohort of patients who were newly initi-
ating insulin, its use was lower than expected in terms of quan-
tity per day, number of claims, and persistence.   Consistent 
predictors of poor persistence with insulin were: use of human 
insulin at index, age (elderly), presence of   mental health 
disorders, increased average copayment for insulin (although 
impact was small), and polypharmacy. Although no formal 
comparisons were conducted, persistence appeared higher 
for patients starting on mixture insulin compared to basal 
insulin. Patients who were excluded because they filled only 
one insulin prescription or used mealtime insulin during the 
postindex period warrant further investigation.
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